Literature DB >> 19124041

Laboratory safe detection of nucleocapsid protein of Rift Valley fever virus in human and animal specimens by a sandwich ELISA.

P Jansen van Vuren1, J T Paweska.   

Abstract

A safe laboratory procedure, based on a sandwich ELISA (sAg-ELISA), was developed and evaluated for the detection of nucleocapsid protein (NP) of Rift Valley fever virus (RVFV) in specimens inactivated at 56 degrees C for 1h in the presence of 0.5% Tween-20 (v/v) before testing. Polyclonal capture and detection immune sera were generated respectively in sheep and rabbits immunized with recombinant NP antigen. The assay was highly repeatable and specific; it detected strains of RVFV from the entire distributional range of the disease, isolated over a period of 53 years; no cross-reactivity with genetically related African phleboviruses or other members of the family Bunyaviridae was observed. In specimens spiked with RVFV, including human and animal sera, homogenates of liver and spleen tissues of domestic ruminants, and Anopheles mosquito homogenates, the sAg-ELISA detection limit ranged from log(10)10(2.2) to 10(3.2) TCID(50)/reaction volume. The ELISA detected NP antigen in spiked bovine and sheep liver homogenates up to at least 8 days of incubation at 37 degrees C whereas infectious virus could not be detected at 48h incubation in these adverse conditions. Compared to virus isolation from sera from RVF patients and sheep infected experimentally, the ELISA had 67.7% and 70% sensitivity, and 97.97% and 100% specificity, respectively. The assay was 100% accurate when testing tissues of various organs from mice infected experimentally and buffalo foetuses infected naturally. The assay was able to detect NP antigen in infective culture supernatants 16-24h before cytopathic effects were observed microscopically and as early as 8h after inoculation with 10(5.8) TCID(50)/ml of RVFV. This ability renders the assay for rapid identification of the virus when its primary isolation is attempted in vitro. As a highly specific, safe and simple assay format, the sAg-ELISA represents a valuable diagnostic tool for use in less equipped laboratories in Africa, and for routine differential diagnosis of viral hemorrhagic fevers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19124041     DOI: 10.1016/j.jviromet.2008.12.003

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  17 in total

1.  The nonstructural protein NSs induces a variable antibody response in domestic ruminants naturally infected with Rift Valley fever virus.

Authors:  José-Carlos Fernandez; Agnès Billecocq; Jean Paul Durand; Catherine Cêtre-Sossah; Eric Cardinale; Philippe Marianneau; Michel Pépin; Noël Tordo; Michèle Bouloy
Journal:  Clin Vaccine Immunol       Date:  2011-11-09

2.  Evaluation of an Indirect Enzyme-Linked Immunosorbent Assay Based on Recombinant Baculovirus-Expressed Rift Valley Fever Virus Nucleoprotein as the Diagnostic Antigen.

Authors:  Bonto Faburay; William C Wilson; Arss Secka; Barbara Drolet; D Scott McVey; Juergen A Richt
Journal:  J Clin Microbiol       Date:  2019-09-24       Impact factor: 5.948

Review 3.  Microfluidic-based approaches for COVID-19 diagnosis.

Authors:  Hsuan-Yu Mu; Yu-Lun Lu; Tzu-Hung Hsiao; Jen-Huang Huang
Journal:  Biomicrofluidics       Date:  2020-12-08       Impact factor: 2.800

4.  Evaluation of Fluorescence Microsphere Immunoassay for Detection of Antibodies to Rift Valley Fever Virus Nucleocapsid Protein and Glycoproteins.

Authors:  I K Ragan; A S Davis; D S McVey; J A Richt; R R Rowland; W C Wilson
Journal:  J Clin Microbiol       Date:  2018-05-25       Impact factor: 5.948

5.  An indirect ELISA of classical swine fever virus based on quadruple antigenic epitope peptide expressed in E.coli.

Authors:  Guo-zhen Lin; Fu-ying Zheng; Ji-zhang Zhou; Xiao-an Cao; Xiao-wei Gong; Guang-hua Wang; Chang-qing Qiu
Journal:  Virol Sin       Date:  2010-02-12       Impact factor: 4.327

6.  Rift Valley fever virus(Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention.

Authors:  Michel Pepin; Michele Bouloy; Brian H Bird; Alan Kemp; Janusz Paweska
Journal:  Vet Res       Date:  2010 Nov-Dec       Impact factor: 3.683

7.  Countermeasure development for Rift Valley fever: deletion, modification or targeting of major virulence factor NSs.

Authors:  Olga Lihoradova; Tetsuro Ikegami
Journal:  Future Virol       Date:  2014-01-01       Impact factor: 1.831

8.  Socio-economic impact of Rift Valley fever to pastoralists and agro pastoralists in Arusha, Manyara and Morogoro regions in Tanzania.

Authors:  Augustino A Chengula; Robinson H Mdegela; Christopher J Kasanga
Journal:  Springerplus       Date:  2013-10-18

9.  Severe Fever with Thrombocytopenia Syndrome Virus Antigen Detection Using Monoclonal Antibodies to the Nucleocapsid Protein.

Authors:  Aiko Fukuma; Shuetsu Fukushi; Tomoki Yoshikawa; Hideki Tani; Satoshi Taniguchi; Takeshi Kurosu; Kazutaka Egawa; Yuto Suda; Harpal Singh; Taro Nomachi; Mutsuyo Gokuden; Katsuyuki Ando; Kouji Kida; Miki Kan; Nobuyuki Kato; Akira Yoshikawa; Hiroaki Kitamoto; Yuko Sato; Tadaki Suzuki; Hideki Hasegawa; Shigeru Morikawa; Masayuki Shimojima; Masayuki Saijo
Journal:  PLoS Negl Trop Dis       Date:  2016-04-05

Review 10.  Rift valley fever: diagnostic challenges and investment needs for vaccine development.

Authors:  Velislava Petrova; Paul Kristiansen; Gunnstein Norheim; Solomon A Yimer
Journal:  BMJ Glob Health       Date:  2020-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.